Dublin, July 07, 2021 (GLOBE NEWSWIRE) -- The "Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026" drug pipelines has been added to ResearchAndMarkets.com's offering.
Chronic obstructive pulmonary disease (COPD) is defined by persistent airflow limitation (reduction in the ability to exhale at a normal rate and volume). While chronic and progressive dyspnea (shortness of breath) is a key symptom, patients may also present with productive cough. Significant exposure to noxious particles or gases, namely tobacco smoke, is the primary cause of the underlying alveolar and airway abnormalities that result in the airflow limitation and respiratory symptoms that characterize the disease. However, other environmental and occupational exposures or genetic abnormalities may also contribute to symptoms.
Latest Key Takeaways
The report estimates that in 2018, there were approximately 307.0 million prevalent cases of chronic obstructive pulmonary disease (COPD) worldwide, and forecasts that number to increase to 328.9 million prevalent cases by 2027.
The "ABCD" GOLD treatment guidelines focus on exacerbation risk and patient-reported outcomes to determine pharmacological treatment strategies, independent of spirometric value.
Dual bronchodilator combinations are being considered as the new gold standard over long-acting muscarinic antagonist (LAMA) Spiriva in the treatment of more severe COPD.
Triple inhaled corticosteroid/long-acting beta 2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) fixed-dose combination therapies delivered through a single inhaler bring convenience to more severe patients. For Breztri Aerosphere's FDA submission, AstraZeneca included data from the KRONOS study, but the ETHOS trial did not complete primary endpoints until mid-2019. As such, the FDA issued a complete response letter to AstraZeneca, benefitting rival GlaxoSmithKline's marketed Trelegy Ellipta as the only triplet on the US market. More recently, Breztri has gained approval in the US and Europe.
IL-5 inhibitors have disappointed in the broader population of more severe COPD patients. However, ongoing studies are evaluating AstraZeneca's Fasenra and GlaxoSmithKline's Nucala in individuals with high eosinophils. Topline results from Fasenra's RESOLUTE and Nucala's MATINEE trials are expected in the coming years, while Phase III results from Sanofi and Regeneron's dual IL-4 and IL-13 inhibitor Dupixent are expected in 2023.
Nebulizers are limited by convenience and often are being developed by smaller companies that lack the commercial resources of large pharma.
Key Topics Covered:
Latest key takeaways
GOLD treatment recommendations
Oral therapies for maintenance treatment
Non-pharmacological management of COPD
KEY REGULATORY EVENTS
Hikma Launches Long-Awaited US Advair Rival
Trixeo Aerosphere Wins EMA Thumbs Up
US FDA Panel Rejects Trelegy Ellipta COPD Mortality Claim; Worries Include Potential Overuse
Cipla Files ANDA For Advair Rival; FDA Will Now Consider Indian Firm's Version Alongside Hikma
Can Glenmark's Triple Therapy Combo Move COPD Treatment Needle?
String Of Positives For Lupin Lifts Outlook
Cipla Granted Approval For First US Proventil Rival
Mylan Launches Advair Rival In Canada
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
Iconovo And Amneal Collaborate On Symbicort Rival
Circassia Ends AZ Deal To Dig Itself Out Of Debt Hole
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
DRUG ASSESSMENT MODEL
Triple therapies will drive modest growth of the COPD market
The impact of nebulized treatment is limited
Biologics present an opportunity that is limited to certain patient subsets
RECENT EVENTS AND ANALYST OPINION
Trelegy Ellipta for COPD (August 31, 2020)
Trelegy Ellipta for COPD (August 28, 2020)
Breztri Aerosphere for COPD (June 24, 2020)
RPL554 (Inhaled) for COPD (March 31, 2020)
Breztri Aerosphere for COPD (October 1, 2019)
KEY UPCOMING EVENTS
Characterizing patient subpopulations
Developing more effective means of managing exacerbations
Improving inhaler technique and compliance
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/zbric7
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900